# Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

> **NCT02348008** · PHASE1,PHASE2 · COMPLETED · sponsor: **Arkadiusz Z. Dudek, MD** · enrollment: 61 (actual)

## Conditions studied

- Clear Cell Renal Carcinoma

## Interventions

- **DRUG:** MK-3475
- **DRUG:** Bevacizumab
- **DRUG:** MK-3475
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02348008
- **Lead sponsor:** Arkadiusz Z. Dudek, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2019-12-05
- **Final completion:** 2019-12-05
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2022-09-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02348008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02348008, "Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02348008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*